Parts Group

Understanding human DNA function by engineering

Our goal is to mechanistically understand impact of mutations in human DNA. To do so, we engineer DNA variation in cells, measure its impact to assay outputs, and quantitatively model the mechanism in between. In the lab, we develop tools for genetic perturbations, and use genome engineering and synthetic biology to create cell lines for randomization, screening, or evaluation. In the office, we develop probabilistic models as well as software tools to accurately and efficiently analyse the readouts.

Research overview

Our goal is to understand how function arises from human DNA, and mutations disrupt it. To do so, we combine genetic perturbation and genome engineering methods with assays of cell state, create accurate and useful quantitative models of the readouts, and disentangle causality by experimenting in multiple contexts.

We are a combined computational and laboratory based research group. In the lab, we adapt, develop, and apply tools for genetic perturbations genomic assays. We engineer the genomes using CRISPR/Cas, prime editing, and recombinase systems to strike the balance of randomization, control, and noise needed to answer our questions. We quantify cell state by growth competition, single cell RNA sequencing, and sorting. Computationally, we model the salient aspects of data generating processes to understand the underlying biology. We create generative models of large scale genetic screens and their outputs, and cast it in software.

Approach

The following four statements describe our approach:

1) We get things done. We start projects with clearly defined goals, and publish both positive and negative results of the ones that pass the pilot stage. We deliver to our collaborators.

2) We work on important problems. We pick projects based on how much they impact our understanding of human cells, characterize the variation of gene function across individuals, or influence how others work.

3) We succeed as a team. We have a diverse mix of backgrounds and skillsets, complementing each other with our strenghts.

4) We are excited about science. We read broadly, discuss latest developments, and keep up to date both with the depth of our field, and the entire breadth of genomics.

Projects

Deciphering genomes through engineered structural variation

While the functions of protein-coding genes are characterized increasingly well, the importance of the non-coding genome content and organization remains poorly understood. This gap is due to a lack of tools for engineering variants

that affect sequence at the scale needed to interrogate gigabases of the human genome.

To bridge this gap, we are developing a toolbox to create deletions, inversions, translocations, and duplications at scale by combining CRISPR prime editing, site-specific recombinases and long-read sequencing. We use these tools to randomize the genome at two scales.

First, we tile enhancer clusters with recombinase sites to understand the grammar of regulatory elements. Second, we target prime editors to repetitive elements to insert hundreds of recombinase sites all across the genome to understand its higher level organisational principles and dispensability

Predicting gene editing outcomes

Cas9

The DNA mutation produced by cellular repair of a CRISPR–Cas9-generated double-strand break determines its phenotypic effect. It is known that the mutational outcomes are not random, but depend on DNA sequence at the targeted location. We systematically study the influence of flanking DNA sequence on repair outcome.

Base editing

CRISPR/Cas base editors promise nucleotide-level control over DNA sequences, but the determinants of their activity remain incompletely understood. We measured base editing frequencies in two human cell lines for two cytosine and two adenine base editors at ∼14 000 target sequences and find that base editing activity is sequence-biased, with largest effects from nucleotides flanking the target base.

Prime editing

Most short sequences can be precisely written into a selected genomic target using prime editing; however, it remains unclear what factors govern insertion. We design a library of 3,604 sequences of various lengths and measure the frequency of their insertion into four genomic sites in three human cell lines, using different prime editor systems in varying DNA repair contexts.

Large scale screens of coding variant effects in humans

We are interested in using genome editing tools, such as base and prime editing, for large scale pooled variant effect screens in human cells and comparing their properties to similar screens using established techniques such as saturation genome editing (SGE). These screens involve generating a pool of cells carrying a library of variants and then subjecting them to a selection pressure related to the gene of interest, which can be intrinsic or artificial, for instance linking activity to fluorescence.

Saturation mutagenesis screens measure the effect of all possible genetic variation in a gene or genomic region in a pooled manner. We are running saturation base editing and prime editing and analyze the data integrated with available SGE data from other groups at Sanger.

Finding sequence determinants of context-specific regulatory elements

Gene expression levels are precisely modulated by regulatory elements, but it is unclear which genes are regulated by which regulatory elements, what the relative contributions are of different regulatory elements, and which transcription factors cause this regulatory activity. We develop tools using synthetic biology approaches to

measure the regulatory activities of sequences at scale. Using this data, we can more systematically analyse how smaller, more controlled DNA changes lead to different regulatory activities. We are exploring how we can engineer new regulatory elements with specific context-specific activities using machine learning models. We hope that this toolbox expands our understanding of how genes are regulated by their sequence context.

Modifiability of CRISPR perturbation effects in iPSCs with scRNA-seq and growth assays

Understanding the role of genetic variants is important to improving the prediction of an individual’s disease onset, risk, severity and treatment outcome. Recent techniques couple CRISPR-based perturbations with single-cell RNA sequencing (scRNA-seq), offering the ability to detect transcriptome-level changes of single cells due to perturbed genomic elements. These approaches have already been used to

characterize cell-specific gene function, identify protein complex membership and predict causal genes. Unlike previous studies, which generally establish proof-of-concept by demonstrating knockout in a handful of genes or focus on a handful of cell-lines, we are performing these experiments at scale by knocking down thousands of genes across hundreds of individuals to then identify role of genetic background in phenotype penetrance.

Using CRISPR-based approaches to identify the genomic drivers of neurodegenerative disease

Human genetics analysis such as GWAS and the rise of population scale biobanks are revealing a growing list of genetic loci associated with neurodegenerative disease. However, even where there exist GWAS loci implicated in disease, the exact causative gene is unclear, as is its role in disease etiology. In collaboration with other labs at the Sanger, we are performing the first systematic comparison of the phenotypic consequences of mutation of different genetic risk factors contributing to Alzheimers disease, Parkinson’s disease and Amyotropic Lateral Sclerosis in iPSC-derived neurons, astrocytes and microglia. This ongoing analysis will connect disease-associated genotypes to disease-relevant cell types and dissect the genetic architecture within and across diseases, assess the most relevant cellular and transcriptomic phenotypes and functionally validate targets from GWAS, network analyses and transcriptomic analysis of patient cells.

Our people

Group lead

Dr Leopold Parts

Group Leader

Leo is focuses on figuring out most important features to measure in individual cells, creating accurate computational models for their readouts, and finding out how they are changed by variation in genomes and surrounding context. Trained in maths and computer science, he now spends his time pondering about statistics and high throughput cell biology.

Core team

Dr Alistair Dunham

Postdoctoral Fellow

Claudia Feng

PhD Student

Mr Gareth Girling

Advanced Research Assistant

Jacob Hepkema

PhD Student

Elin Madli Peets

Advanced Research Assistant

Juliane Weller

PhD Student

Isabelle Zane

PhD Student

Previous core team members

Dr Felicity Allen

Postdoctoral Fellow

Luca Crepaldi

Staff Scientist

Dr Michelle McRae

Senior Research Assistant/Laboratory Manager

Danesh Moradigaravand

Senior Bioinformatician

Dr Daniele Muraro

Senior Bioinformatician

Kasia Tilgner

Visiting Scientist

Dr Yan Zhou

Postdoctoral Fellow

Related groups

Science group

Bayraktar Group

Cellular Genetics

We seek to explore the vast cellular diversity in the human brain using large-scale spatial transcriptomics, imaging and functional screens.

Science group

Cancer Dependency Map Analytics

Cancer, Ageing and Somatic Mutation

We design algorithms and tools to identify all cancer vulnerabilities and genetic dependencies, paving the way to new therapies

Science group

Cellular Generation and Cellular Screening

Scientific Operations

The Cellular Generation and Cellular Screening groups are core facilities that provides central cell biology support to the Sanger Institute, functioning ...

Science group

Cellular Genetics Informatics

Cellular Genetics

Our team provides efficient access to cutting-edge analysis methods, environments and pipelines for Cellular Genetics programme, which leads and is involved ...

Science group

Cellular and Gene Editing Research

Cellular Operations

We develop novel genome editing techniques, cellular differentiation and cellular phenotyping systems, especially with respect to high-throughput investigation of gene and ...

Science group

Garnett Group

Translational Cancer Genomics

The Translational Cancer Genomics team investigate how genetic alterations in cancer contribute to disease and impact on response to therapy.

Science group

Gene Editing

Cellular Operations

In collaboration with our colleagues in Cellular Operations and Stem Cell Informatics, our work focuses on supporting and delivering the gene ...

Science group

Human Cell Atlas - Executive Office (UK)

Administrative Support

The HCA Executive Office, in the UK, is based at the Wellcome Sanger Institute, and works with regional offices in the ...

Science group

Human Genetics Administration

Human Genetics

The Human Genetics Administration comprises a five strong team that provides comprehensive support for the smooth running of the Human Genetics ...

Science group

Human Genetics Informatics (HGI)

Human Genetics

Human Genetics Informatics (HGI) supports the scientific aims of the Human Genetics programme by developing and operating computational analysis workflows, managing ...

Science group

Lehner Group

Programmable biology

We seek to lay the foundations for programmable biology. By combining genomics, biophysics, mechanistic modelling and artificial intelligence at scale, we ...

Science group

Billker Group

Rodent models of malaria

We help create models for high throughput genetic screens carried out in Dr. Billker's group.

Science group

High throughput gene editing

Cellular Operations

The High Throughput Gene Editing team helped to deliver the gene editing requirements of the Institute's faculty and research

Science group

Yusa Group

Stem Cell Genetics

We share many interests with Dr. Kosuke Yusa's group, and collaborate with them on internal projects.

Wellcome Sanger Institute

Programmes and Facilities

Programme

Open Targets

Founded in 2014, Open Targets is an innovative public-private partnership that uses human genetics and genomics data for systematic drug target ...

Programme

Human Genetics

The Human Genetics Programme is driving a step-change in our understanding of genetic causes and biological mechanisms of disease susceptibility and ...

Programme

Generative and Synthetic Genomics

The Generative and Synthetic Genomics Programme combines large-scale data generation and artificial intelligence to lay the foundations for predictive and programmable ...

Partners

We work with the following groups

External

Cancer Dependency Map

The Cancer Dependency Map aims to find a targetable dependency in each cancer cell.

Publications

Loading publications...